Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)

The Beacon (Audio)
28/12/2018 13 min
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)

Listen "Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)"

Descargar episodio Ver en sitio original

Episode Synopsis

Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter.

More episodes of the podcast The Beacon (Audio)

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075) 08/03/2019
Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074) 05/03/2019
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072) 21/12/2018
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071) 11/12/2018
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070) 09/12/2018
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069) 04/12/2018
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068) 02/12/2018
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067) 16/11/2018
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066) 14/11/2018
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065) 08/11/2018
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA